LFLynnette Fernandez-Cuesta

Lynnette Fernandez-Cuesta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lynnette Fernandez-Cuesta has a total of 848 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A multi-omic, spatial, and whole-slide image dataset of lung neuroendocrine tumours

    by Lipika Kalson, Alexandra Sexton-Oates, Emilie Mathian, Catherine Voegele, Alex Di Genova, Zhaozhi Li, Jaehee Kim, Leigh M. Marsh, Luka Brcic, Lynnette Fernandez-Cuesta, et al.

  • Open Access

    Deep molecular profiling of lung neuroendocrine tumours and supra-carcinoids

    by Alexandra Sexton-Oates, Émilie Mathian, Noah Candeli, Yuliya Lim, Catherine Voegele, Alex Di Genova, Laurane Mangé, Zhaozhi Li, Tijmen van Weert, Lipika Kalson, et al.


  • Image dataset of lung neuroendocrine tumours from the lungNENomics cohort

    by Voegele Catherine, Foll Matthieu, Alcala Nicolas, Fernandez-Cuesta Lynnette

  • Lung carcinoids (lung neuroendocrine tumors): integrated classification, molecular biology, diagnosis, and multidisciplinary management

    by Anna Koumarianou, Jules Derks, Marina Tsoli, Marco Volante, Lynnette Fernandez-Cuesta, Vikas Prasad, Pier Luigi Filosso, Benjamin Gibert, Thomas Walter, Alice Durand

    This narrative review aims to provide a comprehensive synthesis of current knowledge and guidelines on lung carcinoids, emphasizing the multidimensional approach required for effective diagnosis and management. The manuscript will: (i) define and classify lung carcinoids in accordance with the latest WHO classification system, and emphasize the importance of molecular markers for precise subtyping; (ii) analyze epidemiological trends, discuss prevalence, incidence, and mortality rates, alongside key risk factors including genetic predispositions (MEN1) and precursor lesions such as diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH); (iii) investigate the etiology and carcinogenesis of lung carcinoids, including insights into the molecular hallmarks and pathways that underlie tumor development and progression; (iv) detail clinical presentations, distinguishing pulmonary symptoms from secretory syndromes (carcinoid syndrome and Cushing syndrome), supported by visual aids to elucidate symptom prevalence and implications; (v) present an integrated diagnostic approach, encompassing state-of-the-art imaging modalities (CT, magnetic resonance imaging [MRI], 68Ga-SSA-positron emission tomography [PET]-CT) and advanced molecular pathology techniques; (vi) outline evidence-based treatment strategies, addressing early-stage interventions, systemic therapies, locoregional therapies, and emerging modalities such as immunotherapy and agnostic approaches; (vii) explore the role of multidisciplinary management, highlighting the critical importance of tumor boards dedicated to lung carcinoids and provide a checklist of key items for comprehensive case discussion and decision-making; and (viii) conclude with future perspectives, identifying gaps in current knowledge and suggest directions for research to enhance diagnosis, treatment, and overall patient quality of life.


  • Open Access

    Basic science and translational implications of current knowledge on neuroendocrine tumors

    by Lynnette Fernandez-Cuesta, Nicolas Alcala, Emilie Mathian, Jules Derks, Chrissie Thirlwell, Talya Dayton, Ilaria Marinoni, Aurel Perren, Thomas Walter, Matthieu Foll

    Neuroendocrine tumors (NETs) are a diverse group of malignancies that can occur in various organs, with a notable prevalence in the lungs and gastrointestinal tract, which are the focus of this Review. Although NETs are rare in individual organs, their incidence has increased over recent decades, highlighting the urgent need for current classification systems to evolve by incorporating recent advances in the understanding of NET biology. Several omics studies have revealed molecular subtypes, which, when integrated into existing classification frameworks, may provide more clinically relevant insights for patients with NETs. This Review examines recent progress in elucidating the biology of NETs, with a particular emphasis on the tumor microenvironment and cells of origin. The existence of different cells of origin, which may contribute to distinct molecular groups, along with profiles of immune infiltration — despite being generally low — could explain the emergence of more aggressive cases and the potential for metastatic progression. Given the molecular heterogeneity of NETs and the diversity of their microenvironments and different cells of origin, there is an urgent need to develop morphomolecular classification systems. Such systems would make it possible to better characterize tumor progression, identify new therapeutic targets, and, ultimately, guide the development of personalized therapies.


  • Open Access

    Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project

    by É. Mathian, Y. Drouet, A. Sexton-Oates, M.G. Papotti, G. Pelosi, J.-M. Vignaud, L. Brcic, A. Mansuet-Lupo, F. Damiola, C. Altun, et al.


  • Open Access

    Multi-omic dataset of patient-derived tumor organoids of neuroendocrine neoplasms

    by Nicolas Alcala, Catherine Voegele, Lise Mangiante, Alexandra Sexton-Oates, Hans Clevers, Lynnette Fernandez-Cuesta, Talya L Dayton, Matthieu Foll

    Organoids are 3-dimensional experimental models that summarize the anatomical and functional structure of an organ. Although a promising experimental model for precision medicine, patient-derived tumor organoids (PDTOs) have currently been developed only for a fraction of tumor types. We have generated the first multi-omic dataset (whole-genome sequencing [WGS] and RNA-sequencing [RNA-seq]) of PDTOs from the rare and understudied pulmonary neuroendocrine tumors (n = 12; 6 grade 1, 6 grade 2) and provide data from other rare neuroendocrine neoplasms: small intestine (ileal) neuroendocrine tumors (n = 6; 2 grade 1 and 4 grade 2) and large-cell neuroendocrine carcinoma (n = 5; 1 pancreatic and 4 pulmonary). This dataset includes a matched sample from the parental sample (primary tumor or metastasis) for a majority of samples (21/23) and longitudinal sampling of the PDTOs (1 to 2 time points), for a total of n = 47 RNA-seq and n = 33 WGS. We here provide quality control for each technique and the raw and processed data as well as all scripts for genomic analyses to ensure an optimal reuse of the data. In addition, we report gene expression data and somatic small variant calls and describe how they were generated, in particular how we used WGS somatic calls to train a random forest classifier to detect variants in tumor-only RNA-seq. We also report all histopathological images used for medical diagnosis: hematoxylin and eosin–stained slides, brightfield images, and immunohistochemistry images of protein markers of clinical relevance. This dataset will be critical to future studies relying on this PDTO biobank, such as drug screens for novel therapies and experiments investigating the mechanisms of carcinogenesis in these understudied diseases.


  • Open Access

    Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites

    by Talya L. Dayton, Nicolas Alcala, Laura Moonen, Lisanne Den Hartigh, Veerle Geurts, Lise Mangiante, Lisa Lap, Antonella F.M. Dost, Joep Beumer, Sonja Levy, et al.


  • Open Access

    Variability of mutational signatures is a footprint of carcinogens

    by Maike L. Morrison, Laurane Mangé, Sergey Senkin, Noah A. Rosenberg, Matthieu Foll, Lynnette Fernandez-Cuesta, Nicolas Alcala

    Understanding the genomic impact of carcinogens is fundamental to cancer biology and prevention. However, recent coordinated efforts to detect such fingerprints have been largely unsuccessful, challenging the paradigm that carcinogens induce identifiable mutational signatures. Here we introduce a new method based on statistics from population genetics, signature variability analysis (SVA), that elucidates both the diversity of tumorcausing processes and the heterogeneity of population carcinogen exposure. When we use SVA to re-analyze four prominent studies commonly cited as evidence of nonmutagenic carcinogens, we find that tumors induced by environmental carcinogens do possess mutational signature patterns that distinguish them from spontaneous tumors, even if a specific mutational signature cannot be detected. We find that, across cancers, organs, and model organisms, carcinogen exposure generally increases both the diversity of mutational signatures within a tumor and the homogeneity of signature activity across subjects. Importantly, we show that this increase in signature diversity, far from being a background effect, is associated with the geographic incidence of cancer and can facilitate the acquisition of cancer driver mutations. Our results both encourage a re-examination of the genomic impact of numerous substances and introduce new tools for the analysis of the genomic effects of other substances, potentially influencing carcinogen classifications and cancer prevention policies.


  • 2199P Immunohistochemical identification of clinical subtypes and potential therapeutic vulnerabilities of lung carcinoids based on multi-omic analysis

    by J. Derks, D. Leunissen, L. Moonen, J. von der Thüsen, M. Den Bakker, L. Hillen, R. van Suylen, R. Damhuis, T. van Den Bosch, L. Lap, et al.